SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as community excitement builds over impending EU approval for its Anktiva therapy and Saudi Arabia's expanding commitment to "all cancers" with IBRX, with many anticipating a significant short squeeze. Investors see the company as deeply undervalued, driven by its innovative immunotherapy's potential for widespread adoption in immune restoration and cancer treatment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and extreme volatility after Novo Nordisk filed a patent infringement lawsuit over its compounded semaglutide products, which Hims has since ceased, with the community sharply divided between concerns over legal and regulatory risks and the belief that the stock is oversold with short-squeeze potential.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl is trending after a sharp stock drop driven by a deteriorated financial outlook, unexpected leadership changes, a delayed filing, and an SEC probe into its accounting practices, leading to a community split between those seeing an oversold buying opportunity and others fearing significant financial irregularities.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

monday.com is experiencing a sharp decline after issuing weaker-than-expected guidance and withdrawing long-term targets, intensifying market fears that AI could disrupt its traditional software business model. The community is sharply divided, with some viewing the brutal sell-off as an overreaction given the company's strong cash position and enterprise growth, while others believe AI tools pose a significant threat to the SaaS sector.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean ($RIG) is trending as the community reacts to its recent all-stock acquisition of Valaris ($VAL) for $5.8 billion, a deal many see as creating a premier offshore drilling leader poised to capitalize on an emerging multi-year upcycle, though some investors are debating the implications of the merger for share dilution and the combined company's future.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following an 'Overweight' initiation and bullish price target from Morgan Stanley, amplifying the narrative around its strategic pivot to AI and high-performance computing data centers. The community is actively discussing the company's strong power infrastructure and key partnerships, like Google, positioning it favorably amidst booming demand for computing capacity, despite some noting its historical correlation with Bitcoin prices.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending amid a significant stock plunge despite a reported earnings beat and new share buyback, fueled by concerns over Meta's Instagram developing a rival app. The community is sharply divided, with many blaming CEO Evan Spiegel's leadership while others see an extreme oversold opportunity given its user growth and AR smartglasses ambitions.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending down sharply after its mixed Q4 earnings report, featuring a revenue miss and conservative forward guidance. This has ignited intense community debate over whether the fintech stock is now severely undervalued and a buying opportunity, or if the market is overreacting amidst broader sector weakness.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is gaining significant attention for its central role in advanced semiconductor packaging, which is vital for the booming AI sector and enhanced by strategic collaborations with industry leaders like Apple, Nvidia, and TSMC. The community views the company as a key beneficiary of the U.S. manufacturing reshoring trend, anticipating substantial long-term growth as it expands its domestic capabilities.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is a major talking point after reporting losses, though management projected a brighter 2026 with an expiring unfavorable slab contract and active strategic partnership discussions with POSCO. The community is sharply divided, with critics citing past underperformance and a significant post-earnings stock drop, while bulls see the stock as deeply undervalued with strong potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galecto (NASDAQ:GLTO) CEO Hans Schambye Sells 700 Shares

Galecto, Inc. (NASDAQ:GLTO - Get Free Report) CEO Hans Schambye sold 700 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.38...

Is the Market Bullish or Bearish on Galecto Inc?

Galecto (NASDAQ:GLTO) Shares Down 13.3% - Time to Sell?

Galecto (NASDAQ:GLTO) Stock Price Down 13.3% - Here's Why...

Small Cap Stocks To Watch Today - November 11th

Spring Valley Acquisition, enGene, Canadian Solar, Galecto, RealReal, Daily Journal Corp. (S.C.), and Navitas Semiconductor are the seven Small Cap stocks to watch today, according to MarketBeat's...

Small Cap Stocks To Research - November 10th

Spring Valley Acquisition, Galecto, Movano, Papa John's International, Strive, Inflection Point Acquisition Corp. II, and Direxion Daily PLTR Bull 2X Shares are the seven Small Cap stocks to watch...

<ul class="summary-bullets"><li>Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.</li><li>The deal adds Damora’s portfolio of mutant calreticulin–targeting antibody therapies for rare blood cancers, with early human trial data expected in 2027.</li><li>The acquisition positions Galecto to focus on next-generation treatments for myeloproliferative neoplasms, expanding its cancer pipeline alongside its ongoing AML drug program.</li></ul>Shares of Galecto surged nearly&nbsp;25% in premarket trading on Tuesday after the biotech firm announced the acquisition of Damora Therapeutics, a private company developing next-generation antibody drugs for rare blood cancers.<h2 class="st-heading-2">Galecto Bets Big On Blood Cancer Therapies</h2>The acquisition gives Galecto control of Damora’s pipeline of mutant calreticulin (mutCALR)-targeting therapies, including DMR-001, a monoclonal antibody that aims to treat two difficult-to-manage bone marrow cancers, which are essential thrombocythemia and myelofibrosis. The company said the drug could be “best in class,” with the potential to work across a broad range of disease-driving mutations.As part of the deal, Galecto raised $285 million in a private round that drew some of the biggest names in biotech investing, including Viking Global Investors, RA Capital Management, Wellington Management, Blackstone, BB Biotech, and Andreessen Horowitz’s a16z Bio + Health. The funding gives the company enough cash to operate well into 2029, with early human trial data for DMR-001 expected in 2027.<h2 class="st-heading-2">A New Chapter For Galecto</h2>Galecto CEO Hans Schambye called the deal a “pivotal milestone” that positions the company to accelerate next-generation treatments for blood cancers driven by mutCALR, which account for roughly 25% of essential thrombocythemia and 35% of myelofibrosis cases in the U.S.Incoming board member Peter Harwin, managing partner at Fairmount, said the combined financial and clinical resources will enable Galecto to advance DMR-001 from preclinical to human testing by mid-2026, with the goal of offering a safer, more convenient treatment option for patients.<h2 class="st-heading-2">Growing Its Cancer Pipeline</h2>Beyond Damora’s assets, Galecto said it’s also advancing its own drug, GB3226, for acute myeloid leukemia (AML). The compound will be featured at the American Society of Hematology’s annual meeting in December, with an FDA filing expected in early 2026 to begin human testing.<h2 class="st-heading-2">Stocktwits Users Eye Multi-Day Rally</h2>On Stocktwits, retail sentiment for Galecto was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:962/134;" src="https://news.stocktwits-cdn.com/glto_ss_jpg_87be36e195.webp" alt="glto ss.jpg" width="962" height="134"><figcaption>GLTO sentiment and message volume as of November 11 | Source: Stocktwits</figcaption></figure>One user speculated that Galecto’s stock could turn into a “multi-day runner,” hinting at continued momentum after its sharp surge.<stembedurl>https://stocktwits.com/Bcscoatings/message/635686140</stembedurl>Another user was far more bullish, predicting the stock could hit $50 next and even climb toward $150.<stembedurl>https://stocktwits.com/BearBullRunner/message/635681400</stembedurl><a href="https://stocktwits.com/symbol/GLTO">Galecto’s stock</a> has surged by more than 270% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Galecto Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally

Galecto announced the acquisition of Damora Therapeutics and a $285 million private raise backed by major biotech investors, including Viking Global, RA Capital, and a16z Bio + Health.

Equity

Shares of biotechnology company Galecto, Inc. (GLTO) soared 632% in the pre-market session on Tuesday. The stock is on track to hit over two-year highs.Galecto is focused on developing treatments for oncological and liver diseases. Its pipeline consists of drug candidates that target cancer and fibrosis signaling pathways, including GB1211 for the treatment of liver cirrhosis, GB1211 in combination with a checkpoint inhibitor for various oncology indications, and GB3226 for multiple genetic subsets of Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GLTO">GLTO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1362/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_8_17_12_AM_png_631ad32651.webp" alt="GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1362" height="124"><figcaption>GLTO's Sentiment Meter and Message Volume as of 8:17 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that this is a pump-and-dump move.<stembedurl>https://stocktwits.com/moneytra1n/message/631281671</stembedurl>Another believes that the rally could be short-lived.<stembedurl>https://stocktwits.com/come_litaliano/message/631283183</stembedurl>In August, Galecto CEO Hans Schambye announced that the company is looking forward to submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2026 for its lead program, GB3226. Preclinical data support the therapeutic potential of the candidate as a monotherapy and in combination to address the menin-resistant population within AML, the company said.Galecto ended the second quarter with approximately $10.2 million in cash and cash equivalents. Last month, it said that it expects this amount to be sufficient to fund operating expenses and capital requirements into 2026, including the submission of the investigational new drug application for GB3226.The company also noted that it would require substantial additional capital to finance its operations, including future clinical development of its GB3226 and GB1211 programs.GLTO stock is down by 20% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jlr-begins-phased-restart-of-operations-more-than-a-month-after-cyber-incident/ch6P7elR3WM">JLR Begins Phased Restart Of Operations More Than A Month After Cyber Incident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GLTO Stock Rises A Whopping 632% Pre-Market, But Retail Investors Remain Cautious

Galecto is focused on developing treatments for oncological and liver diseases.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

GLTO
Galecto Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLTO News

GLTOGalecto Inc